Immunicon Corp. Of Huntingdon Valley developed the CellSearch? System under development, license and supply agreement with Veridex, company Veridex, a Johnson & Johnson, – – About Veridex, LLC develops cancer diagnostic products allow that earlier detection of diseases more accurate staging, monitoring and therapeutic selection. The company is initially developing two complementary product lines: CellSearch? identify, enumerate and characterize circulating tumor cells directly from whole blood and Gene Search? The molecular technology use to diagnose, stage, and precisely to characterize tumors. For more information.

Researchers worked with a 83 – patient subset of 177 patients with metastatic breast cancer in a in a multi-organ, double-blind study, 7.5 mL the New England Journal of Medicine . To get the most directly comparable results, the subgroup of patients whose cancer recurred, but who had not received any treatment, thereby limiting aggravating factors such as differences between the prior therapies, or stage and the time of treatment. Patients were tested for CTC count before the first treatment and then every four weeks were clinically out to 18 months..These figures are even more convincing if the complexity of the patients is taken into consideration. The majority of patients. Already be plurality of any other diagnostic test subjected before the cardiovascular magnetic resonance investigation These figures emphasize a value of in cardiovascular magnetic resonance in clinical cardiology practical. Research and education the using as first magnetic engineering rather than vascular late in for diagnosing patients taken into account.

Non-clinical studies Development Programme on HYSTEM – Rx than a cell of conveyor device of reconstructive surgery and other cell-based therapies.